- Report
- October 2024
- 200 Pages
Global
From €3348EUR$3,750USD£2,911GBP
- Report
- May 2024
- 200 Pages
Global
From €3705EUR$4,150USD£3,221GBP
- Report
- May 2024
- 200 Pages
Global
From €3705EUR$4,150USD£3,221GBP
- Report
- March 2024
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- October 2024
- 318 Pages
Global
From €5678EUR$6,360USD£4,937GBP
€7097EUR$7,950USD£6,171GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- March 2024
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- March 2024
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- March 2024
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- March 2024
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP
- Report
- March 2024
- 30 Pages
Global
From €2321EUR$2,600USD£2,018GBP
€2901EUR$3,250USD£2,523GBP

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life.
The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more